SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma informs about press release

15 Dec 2015 Evaluate

Natco Pharma has informed about a Press Release dated December 15, 2015 titled ‘NATCO receives generic Ledipasvir + Sofosbuvir approval for India’.

The above information is a part of company’s filings submitted to BSE.

Natco Pharma Share Price

1154.55 -19.45 (-1.66%)
11-May-2026 09:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1842.30
Dr. Reddys Lab 1278.10
Cipla 1336.80
Zydus Lifesciences 932.30
Lupin 2273.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×